Back Mirtazapien Afrikaans ميرتازابين Arabic میرتازاپین AZB Mirtazapin Czech Mirtasapin Welsh Mirtazapin German Μιρταζαπίνη Greek Mirtazapina Spanish میرتازاپین Persian Mirtatsapiini Finnish
Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression.[10][11] Its effects may take up to four weeks but can also manifest as early as one to two weeks.[11][12] It is often used in cases of depression complicated by anxiety or insomnia.[10][13] The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants.[14] It is taken by mouth.[11]
Common side effects include sleepiness, dizziness, increased appetite and weight gain.[11] Serious side effects may include mania, low white blood cell count, and increased suicide among children.[11] Withdrawal symptoms may occur with stopping.[15] It is not recommended together with a monoamine oxidase inhibitor,[11] although evidence supporting the danger of this combination has been challenged.[16] It is unclear if use during pregnancy is safe.[11] How it works is not clear, but it may involve blocking certain adrenergic and serotonin receptors.[10][11] Chemically, it is a tetracyclic antidepressant,[11] and is closely related to mianserin. It also has strong antihistaminergic effects.[10][11]
Mirtazapine came into medical use in the United States in 1996.[11] The patent expired in 2004, and generic versions are available.[11][17] In 2021, it was the 124th most commonly prescribed medication in the United States, with more than four million prescriptions.[18][19]
- ^ Cite error: The named reference
IndexNominum2000was invoked but never defined (see the help page). - ^ Cite error: The named reference
Drugs.comwas invoked but never defined (see the help page). - ^ "Mirtazapine Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 22 August 2020. Retrieved 4 March 2020.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ a b c d e f g Timmer CJ, Sitsen JM, Delbressine LP (June 2000). "Clinical pharmacokinetics of mirtazapine". Clinical Pharmacokinetics. 38 (6): 461–474. doi:10.2165/00003088-200038060-00001. PMID 10885584. S2CID 27697181.
- ^ a b c d e "REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA]". DailyMed. Organon Pharmaceuticals USA. October 2012. Archived from the original on 10 January 2021. Retrieved 24 October 2013.
- ^ a b c d e Cite error: The named reference
AXITwas invoked but never defined (see the help page). - ^ a b c d e Cite error: The named reference
EMCwas invoked but never defined (see the help page). - ^ a b c d e f Anttila SA, Leinonen EV (2001). "A review of the pharmacological and clinical profile of mirtazapine". CNS Drug Reviews. 7 (3): 249–264. doi:10.1111/j.1527-3458.2001.tb00198.x. PMC 6494141. PMID 11607047.
- ^ a b c d e f g h i j k l "Mirtazapine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 10 January 2021. Retrieved 20 November 2018.
- ^ Cite error: The named reference
Cochrane2011was invoked but never defined (see the help page). - ^ Nutt DJ (June 2002). "Tolerability and safety aspects of mirtazapine". Human Psychopharmacology. 17 (Suppl 1): S37–S41. doi:10.1002/hup.388. PMID 12404669. S2CID 23699759.
- ^ "[129] Mirtazapine: Update on efficacy, safety, dose response". www.ti.ubc.ca. Archived from the original on 7 May 2021. Retrieved 8 May 2021.
- ^ British national formulary : BNF 74 (74 ed.). British Medical Association. 2017. p. 354. ISBN 978-0857112989.
- ^ Cite error: The named reference
pmid16342227was invoked but never defined (see the help page). - ^ Schatzberg AF, Cole JO, DeBattista C (2010). "3". Manual of Clinical Psychopharmacology (7th ed.). Arlington, VA: American Psychiatric Publishing. ISBN 978-1-58562-377-8.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Mirtazapine - Drug Usage Statistics". ClinCalc. Archived from the original on 20 October 2020. Retrieved 14 January 2024.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search